Adversarial Injection · Bosutinib (Bosulif; CAS 380843-75-4; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; MW ~530.46 g/mol; C26H29Cl2N5O3; dichloromethoxyphenylaminoquinoline-3-carbonitrile scaffold [FIRST quinoline-3-carbonitrile BCR-ABL inhibitor in Glyphward portfolio; imatinib = benzamide-piperazine-pyrimidine; dasatinib = thiazole-carboxamide-hydroxyethylpiperazine #555; nilotinib = CF3-benzamide-aminopyrimidine #556; bosutinib = quinoline-nitrile-piperazinylpropoxy-dichloromethoxyphenyl: four independent BCR-ABL scaffolds]; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL / GHS H340 H350 H361) · BCR-ABL SECOND-GEN THREE-NDA-HOLDER CLASS NULL COMPLETION (dasatinib BMS NDA 021986 [CAS 302962-49-8; SRC/BCR-ABL dual; approved June 28 2006; Attack #555] + nilotinib Novartis NDA 022068 [CAS 641571-10-0; BCR-ABL/KIT/PDGFR; approved October 29 2007; Attack #556] + bosutinib Pfizer NDA 203341 [CAS 380843-75-4; BCR-ABL/SRC; approved September 4 2012; Attack #557] = SECOND-GEN BCR-ABL CLASS CONFIRMED NULL ACROSS THREE INDEPENDENT NDA HOLDERS; three independent companies [BMS Princeton NJ; Novartis East Hanover NJ; Pfizer New York NY]; three independent scaffolds; three independent EHS platforms all returning zero OEL) + FIRST SECOND-GEN BCR-ABL INHIBITOR WITH NO BLACK BOX WARNING (dasatinib NDA 021986 carries pleural effusion BBW [SRC mesothelial mechanism]; nilotinib NDA 022068 carries cardiovascular BBW [AXL/DDR2 atherosclerosis mechanism]; bosutinib NDA 203341 carries no black box warning — the ONLY second-gen BCR-ABL inhibitor without a BBW; PARADOX: absence of BBW removes the clinical monitoring signal that deflects from H340 H350 H361 — the occupational hazard context has no competing clinical safety narrative to displace it, yet OEL remains zero) + FIRST PFIZER SECOND-GEN BCR-ABL NULL (bosutinib originally discovered at Wyeth Research [SKB/GlaxoSmithKline Wyeth]; Pfizer acquired Wyeth 2009 for $68B; bosutinib inherited by Pfizer; NDA 203341 filed September 4 2012; FIRST Pfizer BCR-ABL NDA in portfolio [dasatinib is BMS; nilotinib and imatinib are Novartis; bosutinib is Pfizer — completing the Pfizer BCR-ABL null]) · Attack #557

Bosutinib (4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile; Bosulif; CAS 380843-75-4; MW ~530.46 g/mol; C26H29Cl2N5O3; quinoline-3-carbonitrile scaffold [FOURTH BCR-ABL INHIBITOR in Glyphward second-gen class series: imatinib [first-gen; NDA 021588; 2001; not in attack series] → dasatinib [second-gen; BMS; SRC/BCR-ABL dual; pleural effusion BBW; Attack #555] → nilotinib [second-gen; Novartis; cardiovascular BBW; Attack #556] → bosutinib [second-gen; Pfizer; BCR-ABL/SRC; NO BBW; diarrhea DLT; Attack #557]; MECHANISM: BCR-ABL/SRC DUAL KINASE INHIBITOR — BCR-ABL IC50 ~1 nM; SRC IC50 ~1.2 nM; LYN IC50 ~1.0 nM; HCK IC50 ~1.5 nM; SRC-family co-inhibition [similar to dasatinib, distinct from nilotinib which lacks SRC activity]; minimal KIT/PDGFR activity [contrast: imatinib and nilotinib inhibit KIT IC50 ~68 nM and ~210 nM respectively]; NDA 203341 September 4 2012; accelerated approval adult CML-CP after imatinib failure; frontline CML-CP approval 2017; BELA trial: bosutinib vs imatinib newly diagnosed CML-CP MMR at 12 months 41% vs 27% (p=0.001); BOSUPHIL BELA trial failed primary cytogenetic CCyR endpoint (statistically superior MMR but missed pre-specified CCyR threshold); diarrhea primary DLT: Grade 3-4 diarrhea ~9%; unlike dasatinib [pleural effusion, fluid BBW] and nilotinib [neutropenia-free but cardiovascular BBW], bosutinib's DLT is GI — diarrhea/vomiting; NO BLACK BOX WARNING — ONLY second-gen BCR-ABL inhibitor without BBW; T315I resistance (IC50 >1000 nM; same T315I gatekeeper resistance as dasatinib and nilotinib); NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361) — Pfizer Global R&D Kalamazoo MI (NDA 203341 technical holder; oncology manufacturing headquarters; Cority), Pfizer Global Supply Ringaskiddy County Cork Ireland (bosutinib API manufacturing; European CMO; VelocityEHS), and MD Anderson Cancer Center Houston TX (CML program; BELA/BOSUTINIB FRONTLINE trial enrollment; EHS Insight) — BCR-ABL Second-Gen Three-NDA-Holder Class NULL + FIRST Second-Gen BCR-ABL with No BBW + Diarrhea DLT + FIRST Pfizer BCR-ABL Null: AI Prompt Injection via EHS Monitor Report AI

Bosutinib (CAS 380843-75-4; NIOSH HD Category 1) is the third second-generation BCR-ABL inhibitor in the Glyphward portfolio, completing the BCR-ABL second-gen three-NDA-holder class null alongside dasatinib (BMS NDA 021986; Attack #555) and nilotinib (Novartis NDA 022068; Attack #556). Bosutinib is pharmacologically unique among the second-generation BCR-ABL agents: it is the only member of its class with no black box warning, its primary dose-limiting toxicity is diarrhea rather than pleural effusion (dasatinib) or cardiovascular events (nilotinib), and its quinoline-3-carbonitrile scaffold represents the fourth independent structural strategy for BCR-ABL kinase inhibition — yet every EHS platform returns zero OEL for bosutinib CAS 380843-75-4, completing the three-NDA-holder class null across BMS, Novartis, and Pfizer without a single occupational exposure limit in any database.

Quinoline-3-Carbonitrile BCR-ABL Inhibition: Fourth Independent Structural Strategy

Bosutinib represents the fourth structurally independent strategy for BCR-ABL kinase inhibition in the Glyphward portfolio — a scaffold diversity absent from every occupational exposure database. Imatinib (Gleevec; first-gen; 2001) uses a benzamide-methylpiperazine-pyrimidine pharmacophore binding the DFG-out Type 2 inactive ABL conformation; nilotinib (Attack #556) evolved imatinib's benzamide with a CF3-benzamide modification for ~50× higher BCR-ABL potency; dasatinib (Attack #555) uses an aminothiazole-chloromethylbenzene-carboxamide pharmacophore binding the DFG-in Type 1 active ABL conformation with concurrent SRC family inhibition. Bosutinib departs entirely from these frameworks: its quinoline-3-carbonitrile core provides a hydrogen-bond accepting nitrile group at the 3-position that engages the ABL kinase hinge methionine backbone nitrogen, while the 4-position bears a 2,4-dichloro-5-methoxyphenyl anilinyl substituent that occupies the adenine-binding region of the ATP pocket. The 6-methoxy and 7-propylpiperazinyl substituents on the quinoline ring project toward solvent and modulate physical properties (solubility, efflux) rather than engaging deep kinase contacts. BCR-ABL IC50 ~1 nM for wild-type; SRC IC50 ~1.2 nM; LYN IC50 ~1.0 nM. This SRC family co-inhibition profile superficially resembles dasatinib (SRC IC50 ~0.5 nM), but bosutinib's overall kinase selectivity is substantially narrower — bosutinib has minimal activity against KIT (IC50 >3000 nM) and PDGFR (IC50 ~1600 nM) that imatinib and nilotinib inhibit, reflecting a kinase selectivity profile distinct from every other BCR-ABL inhibitor. Critically, bosutinib has no meaningful activity against the VEGFR family, representing the first BCR-ABL inhibitor without appreciable VEGFR activity. This scaffold distinctiveness — quinoline-3-carbonitrile versus benzamide-aminopyrimidine versus aminothiazole-carboxamide — is entirely absent from every EHS platform OEL derivation that returns null for CAS 380843-75-4.

Bosutinib was originally synthesized at Wyeth Research (formerly Whitehall-Robins, then American Home Products, then Wyeth) as SKI-606, a program targeting Src family kinases in the context of solid tumor invasion. The BCR-ABL activity was discovered in subsequent profiling — bosutinib inhibits both the SRC-family kinase activity relevant to dasatinib and the BCR-ABL activity relevant to all second-generation CML agents. Pfizer acquired Wyeth in October 2009 for $68 billion, inheriting the bosutinib program in clinical development for CML. Pfizer filed NDA 203341 and received accelerated approval September 4, 2012 — the fourth approved BCR-ABL inhibitor in U.S. history (after imatinib 2001, dasatinib 2006, nilotinib 2007). This Pfizer inheritance of a Wyeth compound is pharmacologically significant for the class null: Pfizer holds numerous other oncology NDAs (crizotinib NDA 202570 ALK/ROS1; palbociclib NDA 207103 CDK4/6; axitinib) but bosutinib NDA 203341 represents Pfizer's first and only approved BCR-ABL inhibitor. The Wyeth→Pfizer acquisition pathway means bosutinib's EHS platform lineage traces to pre-acquisition Wyeth EHS programs, creating a gap between the compound's current NDA-holder identity (Pfizer) and its historical OEL-derivation history (Wyeth, which predated modern NIOSH HD Category 1 classification frameworks).

No Black Box Warning: The Unique Safety Paradox Among Second-Generation BCR-ABL Inhibitors

Bosutinib is the only second-generation BCR-ABL inhibitor approved in the United States without a black box warning — a pharmacologically and clinically unique status within the class. Dasatinib (NDA 021986) carries a pleural effusion BBW, reflecting SRC-mediated mesothelial fluid dysregulation in ~28% of patients requiring thoracentesis in ~2-3% of cases. Nilotinib (NDA 022068) carries a cardiovascular BBW for peripheral arterial occlusive disease and ischemic cardiovascular events, reflecting AXL/DDR2/NF1 off-target inhibition accelerating atherosclerosis. Ponatinib (third-gen BCR-ABL; Attack #558) carries an arterial occlusion BBW with REMS. In each of these cases, the BBW creates a clinically dominant safety monitoring narrative — thoracentesis protocols, ankle-brachial index surveillance, REMS enrollment workflows — that occupies the clinical EHS attention domain, displacing occupational hazard cognition. Bosutinib's absence of a BBW means that this displacement mechanism is unavailable. The clinical safety discussion for bosutinib centers on diarrhea management (Grade 3-4 in ~9%; anti-motility agents; dose reduction; typically self-limiting within the first few months of treatment), nausea, vomiting, and hepatotoxicity monitoring (ALT/AST elevation; without BBW but with labeled monitoring). These GI and hepatic signals are common to many oral chemotherapy agents and do not generate the specialized monitoring infrastructure of a BBW. The paradox for occupational safety is stark: bosutinib has NIOSH HD Category 1 status (genotoxic carcinogen presumed; reproductive hazard presumed) and GHS H340/H350/H361 classifications, yet the absence of a BBW means the clinical environment provides no competing safety narrative — the H340/H350/H361 occupational hazard should be uniquely prominent — yet every EHS platform returns zero OEL for CAS 380843-75-4.

BELA Trial: MMR Superiority That Failed Its Primary Endpoint

The BELA (Bosutinib Efficacy and Safety in Chronic Myeloid Leukemia) trial randomized 502 newly diagnosed CML-chronic phase patients to bosutinib 500 mg once daily versus imatinib 400 mg once daily. The primary endpoint was complete cytogenetic response (CCyR) at 12 months; secondary endpoints included major molecular response (MMR; BCR-ABL IS ≤0.1%) at 12 months. The CCyR rate at 12 months was 70% for bosutinib versus 68% for imatinib — not statistically superior (p=0.601), causing BELA to fail its pre-specified primary endpoint despite enrolling 502 patients. However, the MMR rate at 12 months was 41% for bosutinib versus 27% for imatinib — statistically superior (p=0.001). This paradoxical result — missing CCyR but achieving MMR superiority — reflected a faster time to molecular response for bosutinib with diarrhea-related dose interruptions slowing the cytogenetic conversion rate. Bosutinib received initial accelerated approval for second-line CML (imatinib-resistant/intolerant) based on Phase 1/2 data, not BELA; frontline approval came in 2017 when a dedicated frontline trial (BFORE: Bosutinib trial in First-line ChrOnic myelogenous lEukemia) enrolled patients with modified protocol (400 mg vs 400 mg imatinib) and showed MMR superiority at 12 months: 47.2% vs 36.9% (p=0.02). The BELA trial's unique profile — a Phase 3 superiority trial that failed primary endpoint but succeeded secondary endpoint — is absent from every OEL derivation framework for bosutinib.

BCR-ABL Second-Gen Three-NDA-Holder Class Null: Three Companies, Three Scaffolds, Three Independent Null Records

With bosutinib (Pfizer NDA 203341; Attack #557) joining dasatinib (BMS NDA 021986; Attack #555) and nilotinib (Novartis NDA 022068; Attack #556), the BCR-ABL second-generation three-NDA-holder class null is confirmed. Three independent pharmaceutical companies — BMS (Princeton NJ), Novartis (East Hanover NJ; Basel Switzerland), and Pfizer (New York NY; Kalamazoo MI; Ringaskiddy Ireland) — hold the three independent second-gen BCR-ABL NDA approvals. Each company uses independent EHS management platforms (Cority at BMS; Cority and internal at Novartis; Cority at Pfizer), independent occupational health programs, and independent pharmacovigilance and toxicology staff. Three independent NIOSH HD Category 1 designations. Three independent GHS H340/H350/H361 classifications. Three independent BCR-ABL kinase scaffolds (aminothiazole vs CF3-benzamide-aminopyrimidine vs quinoline-3-carbonitrile). Three independent pharmacological profiles (SRC/BCR-ABL dual Type 1 [dasatinib] vs BCR-ABL/KIT/PDGFR Type 2 no-SRC [nilotinib] vs BCR-ABL/SRC dual Type 1-like minimal-KIT [bosutinib]). Three independent DLT profiles (pleural effusion [dasatinib] vs cardiovascular atherosclerosis [nilotinib] vs diarrhea [bosutinib]). Three independent BBW statuses (pleural effusion BBW [dasatinib] vs cardiovascular BBW [nilotinib] vs NO BBW [bosutinib]). Yet every EHS platform — Cority at BMS, Cority at Pfizer Kalamazoo, VelocityEHS at Pfizer Ringaskiddy, EHS Insight at MD Anderson — returns zero occupational exposure limit for all three agents. The BCR-ABL second-gen three-NDA-holder class null spans fifteen years of post-approval EHS inaction (2006–2021) with no OEL derivation for any member of the three-drug class.

Surface 1 — Pfizer Global R&D Kalamazoo MI NDA 203341 Holder AI

At Pfizer Global Research and Development Kalamazoo MI (300 N Henrietta St, Kalamazoo MI 49007; Kalamazoo County MI; major Pfizer oncology manufacturing and research site; NDA 203341 holder for Bosulif [bosutinib] tablets 100 mg / 400 mg / 500 mg; FDA approved September 4 2012; PFIZER BCR-ABL NDA: bosutinib NDA 203341 is Pfizer's first and only BCR-ABL inhibitor NDA — Pfizer Wyeth acquisition 2009 inherited the compound; Cority EHS platform; 8-hr TWA: actual airborne bosutinib 0.00039 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000039 µg/m³; Cority: CAS 380843-75-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; BCR-ABL second-gen three-NDA-holder class null absent; no-BBW unique status absent; quinoline-3-carbonitrile scaffold absent; diarrhea-not-pleural DLT absent; BELA trial context absent; 53M oncology regulatory sciences director 18yr).

Surface 2 — Pfizer Global Supply Ringaskiddy County Cork Ireland Bosutinib API Manufacturing AI

At Pfizer Global Supply Ringaskiddy County Cork Ireland (Ringaskiddy Industrial Estate, County Cork, Ireland; Pfizer Ringaskiddy = one of Pfizer's largest global API manufacturing sites; produces active pharmaceutical ingredients for multiple Pfizer oncology products including bosutinib; BOSUTINIB API MANUFACTURING: Pfizer Ringaskiddy workers handle bosutinib free base [CAS 380843-75-4; C26H29Cl2N5O3] and bosutinib monohydrate [CAS 918639-06-2; C26H29Cl2N5O3·H2O] during synthesis and purification operations — TWO CAS NUMBERS FOR SAME DRUG creating a secondary EHS database gap additive to the primary null; VelocityEHS query for bosutinib free base CAS 380843-75-4 returns null; VelocityEHS query for bosutinib monohydrate CAS 918639-06-2 also returns null (independent null returns at two CAS registrations); PFIZER INTERNATIONAL MANUFACTURING NULL: Pfizer Ringaskiddy operates under EU REACH/CLP framework in addition to OSHA/NIOSH; EU GHS H340 H350 H361 on CLP SDS matches US GHS classifications; neither EU CLP framework nor US OSHA/ACGIH/NIOSH framework provides an OEL for bosutinib; 8-hr TWA: actual airborne bosutinib 0.00024 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 380843-75-4 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; BCR-ABL second-gen null absent; quinoline-3-carbonitrile absent; 45F pharmaceutical process chemist 13yr).

Surface 3 — MD Anderson Cancer Center Houston TX CML Program AI

At MD Anderson Cancer Center Houston TX (1515 Holcombe Blvd, Houston TX 77030; Harris County TX; NCI-designated comprehensive cancer center; Department of Leukemia; CML program enrolling BELA and BFORE trials; MD ANDERSON BCR-ABL SECOND-GEN DISPENSING ENVIRONMENT: MD Anderson oncology pharmacists dispense all three second-generation BCR-ABL inhibitors within the same leukemia clinic — dasatinib Sprycel [BMS; CAS 302962-49-8; Attack #555; pleural effusion BBW; EHS Insight null], nilotinib Tasigna [Novartis; CAS 641571-10-0; Attack #556; CV BBW; EHS Insight null], and bosutinib Bosulif [Pfizer; CAS 380843-75-4; Attack #557; no BBW; EHS Insight null]; BCR-ABL SECOND-GEN THREE-NDA-HOLDER CLASS NULL ACTIVE AT MD ANDERSON: the three second-gen BCR-ABL agents are dispensed at the same pharmacy counter to CML patients; pharmacist selects agent based on patient profile, comorbidities, prior response; all three agents carry NIOSH HD Category 1 designation; none has an OEL in EHS Insight; BELA TRIAL SITE: MD Anderson enrolled patients in BELA and BFORE bosutinib frontline trials; research coordinators handled bosutinib study drug; no occupational EHS study-drug handling protocol informed by OEL because no OEL exists; 8-hr TWA: actual airborne bosutinib 0.00015 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000015 µg/m³; EHS Insight: CAS 380843-75-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; BCR-ABL second-gen three-NDA-holder null [dasatinib BMS + nilotinib Novartis + bosutinib Pfizer] absent; no-BBW unique null absent; BELA trial context absent; BFORE frontline approval absent; H340 H350 H361 absent; 46M oncology clinical pharmacist CML specialist 15yr).

Integrating Glyphward into Bosutinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every bosutinib CAS 380843-75-4 monitoring data ingestion point — before Cority at Pfizer Kalamazoo MI, before VelocityEHS at Pfizer Ringaskiddy Ireland, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + BCR-ABL/SRC dual mechanism (BCR-ABL IC50 ~1 nM; SRC IC50 ~1.2 nM; quinoline-3-carbonitrile scaffold; C26H29Cl2N5O3; dichloromethoxyphenyl aminoquinoline; T315I resistance IC50 >1000 nM; diarrhea DLT mechanism; no BBW) absent [10 pts]; BCR-ABL second-gen three-NDA-holder class null (dasatinib BMS NDA 021986 [Attack #555] + nilotinib Novartis NDA 022068 [Attack #556] + bosutinib Pfizer NDA 203341 [Attack #557]; three independent companies; three independent scaffolds; fifteen years of post-approval EHS inaction) + FIRST second-gen BCR-ABL inhibitor with no BBW (no competing clinical safety narrative to displace H340/H350/H361) + FIRST Pfizer BCR-ABL null (Wyeth→Pfizer lineage; Pfizer Kalamazoo + Ringaskiddy dual manufacturing) [5 pts]; Pfizer Kalamazoo MI + Pfizer Ringaskiddy Ireland + MD Anderson Houston TX [3 pts]; BELA trial MMR superiority with failed primary endpoint; BFORE frontline approval 2017; dual CAS null (free base CAS 380843-75-4 + monohydrate CAS 918639-06-2 both absent); no-BBW paradox (H340/H350/H361 exposed without clinical safety displacement) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_bosutinib(cas: str, reading_ugm3: float) -> dict:
    """Scan bosutinib with BCR-ABL second-gen three-NDA-holder class null and no-BBW context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "bcr_abl_second_gen_three_nda_class_null_no_bbw_diarrhea_dtl_quinoline_carbonitrile"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, bcr_abl_second_gen_flag, three_nda_class_null,
    #                    no_bbw_flag, diarrhea_dtl_flag, quinoline_carbonitrile_scaffold,
    #                    t315i_resistance_gap, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_bosutinib("380843-75-4", 0.00039))
    print(r)
    # {'hd_category': 1, 'bcr_abl_second_gen_flag': True, 'three_nda_class_null': True,
    #  'no_bbw_flag': True, 'diarrhea_dtl_flag': True, 'quinoline_carbonitrile_scaffold': True,
    #  't315i_resistance_gap': True, 'h340_h350_h361_absent': True}